Online citations, reference lists, and bibliographies.
← Back to Search

A PEGylated Hyaluronic Acid Conjugate For Targeted Cancer Immunotherapy

J. M. Shin, S. Oh, Seunglee Kwon, V. G. Deepagan, Minchang Lee, S. Song, H. Lee, S. Kim, Kwon-Ho Song, T. Kim, J. Park
Published 2017 · Chemistry, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
ABSTRACT The cell‐free approach to foreignizing tumor cells with non‐self antigens has received increasing attention as a method to induce cytotoxic T lymphocyte (CTL)‐mediated immunological rejection of tumors, because the clinical translation of the conventional CTL‐based cancer immunotherapies has been limited by a complicated manufacturing process and autotransplantation. In this study, we prepared matrix metalloproteinase 9 (MMP9)‐responsive polymeric conjugates consisting of PEGylated hyaluronic acid (HA) as the targeting moiety and ovalbumin (OVA) as the model foreign antigen. The MMP9‐cleavable linker was introduced between PEG and the HA backbone to facilitate the detachment of the PEG corona from the conjugate at the tumor site. From the in vitro cellular uptake study, it was revealed that the conjugate was effectively taken up by the CD44‐expressing TC‐1 cancer cells in the presence of MMP9 via receptor‐mediated endocytosis. When the conjugate was systemically administered into the tumor‐bearing mice with endogenous OVA‐specific CTLs, the tumor growth was markedly inhibited, which was attributed to the significant antigen presentation on the tumor cells. Overall, the MMP9‐responsive conjugates bearing foreign antigens might have the potential as an alternative to CTL‐based cancer immunotherapeutics. Graphical abstract Figure. No caption available.
This paper references
10.1016/S0169-409X(02)00226-0
PEGylated Nanoparticles for Biological and Pharmaceutical Applications
H. Otsuka (2003)
10.1016/j.jconrel.2014.12.007
A polymeric conjugate foreignizing tumor cells for targeted immunotherapy in vivo.
Y. Lee (2015)
10.1038/nri1842
Adoptive immunotherapy for cancer: building on success
L. Gattinoni (2006)
10.1016/j.it.2016.01.001
T Cell Vaccinology: Beyond the Reflection of Infectious Responses.
Nathan D Pennock (2016)
10.1158/0008-5472.CAN-12-2796
Acidity generated by the tumor microenvironment drives local invasion.
V. Estrella (2013)
10.1016/j.addr.2009.02.010
PEG conjugates in clinical development or use as anticancer agents: an overview.
G. Pasut (2009)
10.1038/nrd4333
Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery
V. Torchilin (2014)
10.1038/nrclinonc.2016.65
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
D. Khalil (2016)
10.1515/9783111576855-012
G
G.V.T.V. Weerasooriya (1824)
10.1038/gt.2010.106
Efficient Delivery of DNA Vaccines using Human Papillomavirus Pseudovirions
S. Peng (2010)
10.1126/scitranslmed.3008226
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
M. Davila (2014)
10.6004/jnccn.2018.0073
Chimeric Antigen Receptor T-Cell Therapy.
Ndiya Ogba (2018)
10.1039/c4nr04249b
Enzyme-responsive nanomaterials for controlled drug delivery.
Q. Hu (2014)
10.1016/j.biomaterials.2009.09.030
Self-assembled hyaluronic acid nanoparticles for active tumor targeting.
K. Choi (2010)
10.1038/nmat3776
Stimuli-responsive nanocarriers for drug delivery.
S. Mura (2013)
10.1146/ANNUREV.IMMUNOL.20.100201.131730
Lymphocyte-mediated cytotoxicity.
J. H. Russell (2002)
10.1016/J.POLYMDEGRADSTAB.2014.05.003
Amphiphilic hyaluronic acid derivative with the bioreducible bond: Synthesis and its implication for intracellular drug delivery
J. M. Shin (2014)
10.1016/j.tibtech.2014.06.007
Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells
L. Eggermont (2014)
10.1016/j.biomaterials.2010.11.010
PEGylation of hyaluronic acid nanoparticles improves tumor targetability in vivo.
K. Choi (2011)
10.1016/j.blre.2015.10.003
Chimeric antigen receptor T cell therapy: 25years in the making.
S. Gill (2016)
10.1002/1097-4636(20000905)51:3<293::AID-JBM1>3.0.CO;2-T
Temperature-sensitive polymer-nanoshell composites for photothermally modulated drug delivery.
S. Sershen (2000)
10.1016/S1357-4310(00)01686-5
Matrix metalloproteinases: multifunctional contributors to tumor progression.
L. Mccawley (2000)
10.1016/j.cell.2010.03.015
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
K. Kessenbrock (2010)
10.1126/SCIENCE.1067100
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
L. Coussens (2002)
10.1016/j.jconrel.2017.04.012
PEGylation rate influences peptide‐based nanoparticles mediated siRNA delivery in vitro and in vivo
Gudrun Aldrian (2017)
10.1021/acsnano.6b05113
Gold-Nanoclustered Hyaluronan Nano-Assemblies for Photothermally Maneuvered Photodynamic Tumor Ablation.
H. Han (2016)
10.1200/JCO.2005.00.240
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
M. Dudley (2005)
10.1038/mt.2013.17
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.
C. Lamers (2013)
10.1039/c4cc02595d
A hyaluronic acid-methotrexate conjugate for targeted therapy of rheumatoid arthritis.
J. M. Shin (2014)
10.1016/j.jconrel.2014.12.032
Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy.
H. Han (2015)
10.1038/nrclinonc.2016.25
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
D. Khalil (2016)
10.1016/j.jconrel.2016.05.009
Tumor microenvironment-specific nanoparticles activatable by stepwise transformation.
Hye-won Ko (2016)
Multifunctional
V. P. Torchilin (2014)
10.5040/9781474284028.0024
S
A. Kumar (1824)
10.1186/1476-5926-2-S1-S24
The liver sinusoidal endothelial cell hyaluronan receptor and its homolog, stabilin-1 – Their roles (known and unknown) in endocytosis
P. McCourt (2004)
10.1016/j.addr.2015.11.015
Polysaccharide-based nanoparticles for theranostic nanomedicine.
M. Swierczewska (2016)
10.1038/nrc2355
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
S. Rosenberg (2008)
10.1126/science.aaa4967
Adoptive cell transfer as personalized immunotherapy for human cancer
S. A. Rosenberg (2015)
10.1038/nm.3394
Microenvironmental regulation of tumor progression and metastasis
Daniela F. Quail (2013)
10.1038/nri1647
Tuning immune responses: diversity and adaptation of the immunological synapse
P. Friedl (2005)
10.1021/LA040084F
Temperature-sensitive hybrid microgels with magnetic properties.
A. Pich (2004)
10.1038/nrc884
Strategies for MMP inhibition in cancer: innovations for the post-trial era
C. Overall (2002)
10.1002/path.2278
Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome
A. Bergamaschi (2008)
10.1038/nmat2614
Emerging applications of stimuli-responsive polymer materials.
M. C. Stuart (2010)
10.1111/j.1582-4934.2005.tb00355.x
Matrix metalloproteinases and angiogenesis
J. Rundhaug (2005)
10.1016/S1357-4310(99)01615-9
Causes and consequences of tumour acidity and implications for treatment.
M. Stubbs (2000)
10.1016/S1074-7613(00)80255-1
MHC class I-restricted CTL responses to exogenous antigens.
M. Jondal (1996)
10.1016/S0945-053X(01)00186-X
CD44-mediated uptake and degradation of hyaluronan.
W. Knudson (2002)



This paper is referenced by
10.1039/C8NH00417J
DePEGylation strategies to increase cancer nanomedicine efficacy.
L. Kong (2019)
10.1016/j.jconrel.2018.04.015
Hyaluronic acid‐based biopharmaceutical delivery and tumor‐targeted drug delivery system
Gangliang Huang (2018)
10.1016/j.semcancer.2019.07.012
Role of cell surface proteoglycans in cancer immunotherapy.
N. A. Espinoza-Sánchez (2019)
10.1002/smll.201900262
Nanoparticle-Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions.
J. Liu (2019)
10.1515/ntrev-2018-0013
Nanoimmunotherapy – cloaked defenders to breach the cancer fortress
Gayathri Kandasamy (2018)
10.1039/C9NR05371A
The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective.
Yongjiang Li (2019)
10.1002/anie.202002780
Improving Cancer Immunotherapy Outcomes using Biomaterials.
Xiaogang Liu (2020)
10.1016/j.colsurfb.2018.09.076
Delivery of MTH1 inhibitor (TH287) and MDR1 siRNA via hyaluronic acid-based mesoporous silica nanoparticles for oral cancers treatment.
X. Shi (2019)
10.1002/PI.5702
Saccharide‐based nanocarriers for targeted therapeutic and diagnostic applications
Vincent Mukwaya (2019)
10.1186/s40824-018-0131-0
A carboxymethyl dextran-based polymeric conjugate as the antigen carrier for cancer immunotherapy
J. M. Shin (2018)
10.1134/s181123822001004x
PEGylated systems in pharmaceutics
Natalia N. Porfiryeva (2020)
10.1016/j.carbpol.2020.116204
Recent advantage of hyaluronic acid for anti-cancer application: a review of "3S" transition approach.
W. Zhong (2020)
10.1002/adhm.201801320
Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy.
E. Lee (2019)
10.1016/j.apsb.2018.11.006
Transformative hyaluronic acid-based active targeting supramolecular nanoplatform improves long circulation and enhances cellular uptake in cancer therapy
Lu Zhong (2019)
10.3390/polym10101133
Hyaluronic Acid-Based Nanomaterials for Cancer Therapy
J. H. Kim (2018)
10.1016/j.bioorg.2019.01.019
Innovative nano-carriers in anticancer drug delivery-a comprehensive review.
P. Dong (2019)
10.1007/s12274-018-2124-7
Polymer nanoparticles as adjuvants in cancer immunotherapy
Shengxian Li (2018)
10.1007/978-981-32-9804-0_6
Carbohydrate Therapeutics Based on Polymer-Grafted Glyconanoparticles: Synthetic Methods and Applications
K. R. Kunduru (2019)
Semantic Scholar Logo Some data provided by SemanticScholar